Diversified Trust CO Macrogenics Inc Transaction History

Diversified Trust CO

$3.27 Billion
Q3 2024

A detailed history of Diversified Trust CO transactions in Macrogenics Inc stock. As of the latest transaction made, Diversified Trust CO holds 18,097 shares of MGNX stock, worth $59,358. This represents 0.0% of its overall portfolio holdings.

Number of Shares

18,097

Previous 18,097 -0.0%

Holding current value

$59,358

Previous $76,000 22.37%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Jul 16, 2024	BUY	$3.31 - $18.51 $14,785 - $82,684	4,467 Added 32.77%	18,097 $76,000
Q1 2024 Apr 18, 2024	BUY	$9.77 - $21.47 $18,367 - $40,363	1,880 Added 16.0%	13,630 $200,000
Q4 2023 Jan 08, 2024	SELL	$4.48 - $10.11 $1,827 - $4,124	-408 Reduced 3.36%	11,750 $113,000
Q3 2023 Nov 17, 2023	BUY	$4.48 - $6.19 $3,386 - $4,679	756 Added 6.63%	12,158 $56,000
Q4 2022 Jan 17, 2023	SELL	$3.34 - $6.98 $3,874 - $8,096	-1,160 Reduced 9.23%	11,402 $77,000
Q2 2022 Jul 12, 2022	BUY	$2.25 - $9.99 $28,264 - $125,494	12,562 New	12,562 $37,000
Q4 2021 Jan 13, 2022	SELL	$15.91 - $21.88 $173,562 - $238,688	-10,909 Closed	0 $0
Q3 2021 Jan 13, 2022	SELL	$19.74 - $28.7 $31,643 - $46,006	-1,603 Reduced 12.81%	10,909 $228,000
Q2 2021 Jul 20, 2021	BUY	$20.49 - $35.63 $22,190 - $38,587	1,083 Added 9.48%	12,512 $336,000
Q1 2021 May 10, 2021	BUY	$18.99 - $33.2 $11,545 - $20,185	608 Added 5.62%	11,429 $364,000
Q3 2020 Oct 15, 2020	SELL	$24.69 - $31.6 $4,073 - $5,214	-165 Reduced 1.5%	10,821 $273,000
Q2 2020 Jul 07, 2020	BUY	$5.2 - $29.12 $57,127 - $319,912	10,986 New	10,986 $307,000

Others Institutions Holding MGNX

# of Institutions

132

Shares Held

55.4M

Call Options Held

215K

Put Options Held

238K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $202M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Diversified Trust CO, based on Form 13F filings with the SEC.

News

Stay updated on Diversified Trust CO with notifications on news.

Account

Diversified Trust CO Macrogenics Inc Transaction History